TORONTO, Dec. 12, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. (“Transition” or the “Company”) (Nasdaq:TTHI) (TSX:TTH) announced today the first patient has been dosed in a Phase 1 clinical study of type 2 diabetes drug candidate, TT-401. TT-401 is a once-weekly administered peptide being studied for its potential to lower blood glucose levels in patients with type 2 diabetes and accompanying obesity.
